论文部分内容阅读
心绞痛是冠心病临床最常见的一种症状,其经典治疗药物硝酸制剂已有百余年历史。随着药物的不断更新及药学研究的进展,八十年代出现了以钙离子拮抗剂及新型的β受体阻断剂为代表的新型抗心绞痛药物,从而形成当前治疗心绞痛的三大支柱。本文结合国内外文献就抗心绞痛药物的临床若干进展作一简述。一、硝酸酯类1.硝酸甘油:自1846年Sahreron 首次合成以来,至今已有140多年历史,目前仍然是临床医生治疗心绞痛所习用的药物之一。晚近最突出的进展是给药途径及剂型的改进和使用范围的扩大,从而增加了疗效,减少了副作用,使用更为方便,为心绞痛患者的
Angina pectoris is one of the most common clinical symptoms of coronary heart disease. Its classic therapeutic drug nitric acid has been in the history of more than one hundred years. With the continuous update of drugs and advances in pharmaceutical research, the emergence of new anti-anginal drugs represented by calcium ion antagonists and novel β-blockers in the 1980s has formed the three pillars of the current treatment of angina pectoris. This article combined with domestic and foreign literature on the clinical progress of anti-angina drugs for a brief review. Nitric acid esters 1. Nitroglycerin: Since the first synthesis of Sahreron in 1846, it has been more than 140 years old and is still one of the drugs used by clinicians to treat angina pectoris. The most prominent recent progress is the improvement of the route of administration and dosage form and the expansion of the range of use, thus increasing the curative effect, reducing the side effects and using more convenient for the patients with angina